Abstract:Immune factors such as interferon‑ɣ and interleukin 4 belong to the group of cytokines that are dependent on type I/II receptors for their signal transmission. Upon activation, these receptors transmit their signal to the cell nucleus and, thus, modulate gene transcription via a signaling cascade consisting of Janus kinases (JAK). This family of four kinases (JAK 1, JAK 2, JAK 3, and tyrosine kinase 2 (TYK2)) subsequently activate members of the signal transducer and activator of transcription (STAT). This finding turned the JAK/STAT signaling pathway into a pharmacological target for the treatment of inflammatory diseases in which cytokines using type I/II receptors play a pathogenic role. In 2018, the European Medicines Agency (EMA) approved tofacitinib for the treatment of psoriatic arthritis. This was the first approval of a JAK/STAT pathway inhibitor for patients treated by dermatologists and rheumatologists. Since then, several new JAK inhibitors have been approved for dermatologic diseases such as atopic dermatitis, alopecia areata, vitiligo, and plaque-type psoriasis. In addition, JAK inhibitors are being investigated for the treatment of many other skin diseases. Thus, systemic JAK inhibitors complete the spectrum of immunotherapeutics with a broader immunological approach compared to monoclonal antibodies. The low molecular weight of JAK inhibitors enables the preparation of these drugs for both systemic and topical administration. Their utilization could represent a valuable alternative to topical steroids. The safety profile of JAK inhibitors must be taken into account. Possible long-term effects may become apparent in the next few years. This article describes both approved JAK inhibitors and relevant new JAK inhibitors that are promising candidates for approval as therapeutics in dermatology.

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs

JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders

JAK Inhibitors: Prospects in Connective Tissue Diseases

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis

[JAK inhibition in the treatment of inflammatory rheumatic diseases]

Janus Kinases (jaks): the Efficient Therapeutic Targets for Autoimmune Diseases and Myeloproliferative Disorders.

The role of the JAK/STAT signal pathway in rheumatoid arthritis

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story

Chemical JAK inhibitors for the treatment of rheumatoid arthritis

JAK inhibitors in rheumatology

Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus

JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy

Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors

[Janus kinase inhibitors for skin disorders]

Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future